Xenon Pharmaceuticals (Nasdaq: XENE) reported that its Board Compensation Committee approved equity inducement grants for eleven new non-officer employees, effective July 30, 2026, under Nasdaq Listing Rule 5635(c)(4). The grants comprise an aggregate of 32,758 share options and 19,013 restricted share units (RSUs).
The options have a 10-year term and an exercise price of $64.19 per common share, equal to Xenon’s July 30, 2026 closing price. Options vest over four years, with 25% after one year from each employee’s start date and the remainder monthly. RSUs vest 25% annually over four years from the July 30, 2026 grant date. Both awards are issued under Xenon’s Amended and Restated 2025 Inducement Equity Incentive Plan.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Explained
Xenon’s approved inducement awards, effective July 30, 2026, create potential employee claims on underlying common shares: RSUs vest into shares and options carry a $64.19 exercise price, so existing ownership can be diluted as the awards vest or are exercised.
Market Context
-0.69% was the 24-hour reaction recorded after prior inducement-grant event news_id 1077704. The cur...
Analysis
-0.69% was the 24-hour reaction recorded after prior inducement-grant event news_id 1077704. The current employee equity announcement adds to a recurring award pattern, while recent insider activity was net selling and short positioning was classified as low.
Key Figures
New employees:11 employeesShare options:32,758 optionsRestricted share units:19,013 RSUs+5 more
"32,758 share options and 19,013 restricted share units (RSUs)."
Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
kv7 potassium channel openermedical
"a novel, potent KV7 potassium channel opener in Phase 3 clinical trials"
A Kv7 potassium channel opener is a drug that helps certain cellular ‘gates’ called Kv7 channels stay open so potassium can flow out of cells, calming electrical activity in nerves and muscle. For investors, these compounds matter because they can form the basis of treatments for conditions driven by excessive electrical firing—like some seizures, pain, or heart rhythm disorders—so successful candidates can create new medical markets or reduce risks in drug pipelines.
phase 3 clinical trialsmedical
"in Phase 3 clinical trials for the treatment of epilepsy"
Phase 3 clinical trials are large, late-stage studies that test a drug or medical treatment in hundreds to thousands of patients to confirm it is safe and effective and to compare it with existing options. Investors care because positive results are a key step toward regulatory approval and commercial sales, reducing uncertainty much like a full dress rehearsal before a product launch; negative results can sharply reduce a program’s value.
VANCOUVER, BC and BOSTON, MA, July 31, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eleven new non-officer employees consisting of an aggregate of 32,758 share options and 19,013 restricted share units (RSUs).All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of July 30, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of $64.19 per common share, which is equal to the closing price per share of Xenon’s common shares on the grant date of July 30, 2026.The share option grants vest over four years, with 25% vesting on the one-year anniversary of the respective employee’s start date and 1/36th of the remaining options vesting monthly thereafter on the last day of each month, subject to such option recipient’s continued service relationship with the Company. Each option has a 10-year term and is subject to the terms and conditions of the share option agreement and the terms of the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan. The RSUs will vest as to 25% of the underlying shares on each of the first four anniversaries of the grant date of July 30, 2026, subject to such employee’s continued service relationship with the Company. Each RSU grant is subject to the terms and conditions of the restricted share unit award agreement and the terms of the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan.
About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.
For Media: Colleen Alabiso Senior Vice President, Corporate Affairs media@xenon-pharma.com
FAQ
What equity inducement grants did Xenon Pharmaceuticals (XENE) announce on July 31, 2026?
Xenon Pharmaceuticals announced inducement equity grants totaling 32,758 share options and 19,013 restricted share units (RSUs) to eleven new non-officer employees. According to Xenon, these awards were approved on July 30, 2026 as material inducements to employment under Nasdaq Listing Rule 5635(c)(4).
What is the exercise price and term of the new Xenon Pharmaceuticals (XENE) stock options?
The new Xenon stock options have a $64.19 exercise price per common share and a 10-year term. According to Xenon, $64.19 equals the closing price of its common shares on the July 30, 2026 grant date, aligning the awards with market value.
How do the Xenon Pharmaceuticals (XENE) inducement stock options vest for new employees?
The inducement stock options vest over four years, with 25% vesting on the one-year anniversary of each employee’s start date. According to Xenon, the remaining options vest monthly in equal 1/36th installments, subject to each recipient’s continued service with the company.
What is the vesting schedule for Xenon Pharmaceuticals (XENE) restricted share units granted in July 2026?
The RSUs vest in four equal annual installments of 25% each. According to Xenon, vesting occurs on each of the first four anniversaries of the July 30, 2026 grant date, contingent on the employee’s continued service relationship with the company throughout the vesting period.
Under which plan were Xenon Pharmaceuticals (XENE) July 2026 inducement grants issued?
The July 2026 inducement grants were issued under Xenon’s Amended and Restated 2025 Inducement Equity Incentive Plan. According to Xenon, both the stock options and RSUs are subject to this plan and to the specific terms of the applicable option or restricted share unit award agreements.
Why did Xenon Pharmaceuticals (XENE) use Nasdaq Listing Rule 5635(c)(4) for these grants?
Xenon used Nasdaq Listing Rule 5635(c)(4) to grant equity awards as material inducements for employment to new hires. According to Xenon, the stock options and RSUs were approved specifically as inducement grants for eleven new non-officer employees joining the company.
